ReviewCurrent oncology reports2023
Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment.
Review in Current oncology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 37 citations in OpenAlex.
- Real-world study of SHR-1210 plus apatinib in the treatment of BRAF-negative mucosal melanoma: efficacy, safety and implications of precision medicine.Frontiers in immunology · 2026Trial
- Primary mucosal melanoma of the maxillary sinus with spontaneous rupture of liver metastasis.Clinical journal of gastroenterology · 2026Article
- Immunohistochemical Predictors in Head and Neck Mucosal Melanoma.Head and neck pathology · 2026Article
- A Technique for the Generation of Mucosal and Acral Melanoma Cell Lines.Pigment cell & melanoma research · 2026Article
- Interaction of Alkannin with CPEB4 Contributes to Its Antitumor Effects in Melanoma.Biomolecules · 2026Article
- Recent Developments in the Diagnosis and Treatment of Disseminated and Rare Melanoma with Radiotheranostics.ACS pharmacology & translational science · 2026Review
- Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer.Pigment cell & melanoma research · 2026Review
- Primary Gingival Mucosal Melanoma: A Case Report and Comparison With Cutaneous Melanoma.Cureus · 2026Article
- Epidemiology of Four Major Canine Tumours in the UK: Insights From a National Pathology Registry With Comparative Oncology Perspectives.Veterinary and comparative oncology · 2026Article
- Analysis of Treatment Patterns for Mucosal Melanoma Using Real-World Data in the SEER-Medicare-Linked Database.Cancer medicine · 2026Article
- Hypomelanotic melanoma of the mandibular gingiva: a case report and literature review.BMC oral health · 2026Review
- Genomic profiling and therapeutic targets of Thai melanoma revealed by next-generation sequencing.Scientific reports · 2026Article
- Pembrolizumab With Anlotinib in Advanced Oral Mucosal Melanoma: A Retrospective Trial.Oral diseases · 2026Article
- Applications and research progress of PET/CT in dynamic monitoring of immunotherapy in melanoma.Journal of translational medicine · 2026Review
- Mucosal melanoma: clinicopathological, molecular and prognostic features in a retrospective cohort.Virchows Archiv : an international journal of pathology · 2026Article
- Unmasking the Silent Invader: A Rare Case of Oral Mucosal Malignant Melanoma With Rapid Multisystem Dissemination.Cureus · 2026Article
- Complete Response to Nivolumab-Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First-Line Nivolumab-Ipilimumab: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Prognostic factors and treatment outcomes in female genital tract melanoma: a 10-year retrospective cohort study.World journal of surgical oncology · 2026Article
- Primary melanoma of the gastrointestinal tract.World journal of gastroenterology · 2026Review
- Multimodality Imaging in Cardiac Metastasis of Cutaneous Melanoma: Case Report and Systematic Review.Journal of cardiovascular development and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewSummarize the writings published in the last years on the management and novel therapies of mucosal melanoma (MM). RECENT
findingsNew research has demonstrated a difference between MM and cutaneous melanoma (CM) in their genomic and molecular landscapes, explaining the response's heterogeneity. Immunotherapy and targeted therapy have limited benefit, but novel therapies are rapidly expanding. MM is aggressive cancer occurring in gastrointestinal, respiratory, or urogenital mucosa; whose incidence is greater in the Asian population. The etiology and pathogenesis remain unclear since UV exposure is not a proven risk factor as in cutaneous melanoma. In contrast to CM, lesions on the mucosal surface are less likely to be recognized early; therefore, the disease is diagnosed in an advanced stage. Clinical manifestations, such as bleeding or pain, can help to detect this tumor, although the prognosis remains unfavorable with an overall 5-year survival rate of less than 20%. The mutational landscape of MM includes mutations of BRAF and NRAS, as well as mutations in the c-KIT/CD117 gene (in 50% of patients), thus limiting therapeutic interventions to immunotherapy. However, clinical studies show less responsiveness to immunotherapy compared to CM, therefore novel therapeutic strategies targeting new molecules are needed to improve the survival of patients with MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.